Glaucoma, Vision & Longevity: Supplements & Science

VisualFieldTest.com

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

  1. 1d ago

    Can Glaucoma Damage Be Reversed? First Human Epigenetic Reprogramming Trial Targets the Optic Nerve

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/can-glaucoma-damage-be-reversed-first-human-epigenetic-reprogramming-trial-targets-the-optic-nerve Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Can Glaucoma Damage Be Reversed? First Human Epigenetic Reprogramming Trial Targets the Optic Nerve Updated August 11, 2026 Bottom line ER-100 is the first human clinical trial of a partial epigenetic reprogramming therapy, but it is not yet evidence that glaucoma damage can be reversed in people. Life Biosciences is testing ER-100 in a small, first-in-human Phase 1 study involving adults with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The treatment delivers genetic instructions for three transcription factors—OCT4, SOX2, and KLF4, collectively called OSK—to retinal ganglion cells using an adeno-associated virus type 2 vector. Oral doxycycline is then used for eight weeks to activate the therapeutic genes. [ClinicalTrials.gov study record] () The scientific idea is fundamentally different from conventional glaucoma treatment. Instead of lowering intraocular pressure, ER-100 is intended to make damaged but living retinal ganglion cells behave more like younger, healthier cells. The preclinical evidence is unusually ambitious: studies in mice reported retinal ganglion cell survival, optic nerve axon growth, improved electrical retinal responses, and improved visual behavior. Company-presented nonhuman-primate data reported recovery of pattern electroretinogram responses and improved optic nerve axon survival after an experimental optic nerve stroke. However, the primate findings have been publicly described mainly through company disclosures and a 2023 Association for Research in Vision and Ophthalmology presentation rather than a detailed, independent, peer-reviewed clinical-efficacy publication. [Nature study] () [Life Biosciences primate disclosure] () As of August 11, 2026, no human vision benefit, epigenetic reset, retinal ganglion cell regeneration, or long-term safety result has been publicly reported. Life Biosciences has confirmed that the first participant was dosed, but the trial remains an early safety study with no results posted on ClinicalTrials.gov. [Life Biosciences first-dose announcement] () [ClinicalTrials.gov record] () The fairest conclusion is: > Glaucoma has not yet entered the era of proven optic-nerve restoration. It has entered the era of the first credible human experiment testing whether optic-nerve cells can be rejuvenated rather than merely protected. --- Why current glaucoma treatments do not reverse damage Glaucoma damages retinal ganglion cells, the nerve cells that collect visual information from the retina. Their long axons form the optic nerve and carry signals to the brain. Once retinal ganglion cells and their axons are permanently lost, current treatments cannot replace them. Standard treatments—including eye drops, laser treatment, and glaucoma surgery—primarily reduce intraocular pressure. Lowering pressure can slow or prevent additional optic nerve damage, but it does not normally restore lost visual field. [National Eye Institute] () [American Academy of Ophthalmology patient information] () This is why glaucoma care is generally described as preservation rather than restoration. Lowering pressure remains the only proven treatment strategy for controlling ordinary open-angle glaucoma, although disease progression can sometimes continue even when pressure is considered acceptable. [National Institute for Health and Care Excellence] () The difficulty is not only that retinal ganglion cells die. Their axons must also travel through the optic nerve and connect with appropriate visual centers in the brain. The National Eye Institute has emphasized that the failure of adult human retinal ganglion cells to regenerate and reconnect explains much of the irreversibility of optic-nerve-related vision loss. [National Eye Institute optic-nerve regeneration report] () ER-100 is designed to intervene at a different level: Conventional treatment: reduce the mechanical stress caused by intraocular pressure. ER-100: alter gene regulation inside retinal ganglion cells. Potential goal: preserve stressed cells, restore the function of injured cells, and possibly reactivate some regenerative capacity. ER-100 is therefore not a replacement for pressure control. Even if it works, a person with glaucoma would still be expected to need standard treatment to reduce the original disease stress. --- What ER-100 is ER-100 is described by Life Biosciences as AAV2-OSK: an adeno-associated virus type 2 vector carrying genetic instructions for OCT4, SOX2, and KLF4. The vector is administered by an intravitreal injection, meaning an injection into the gel-like vitreous cavity inside the eye. [Life Biosciences] () The vector is intended to deliver the OSK instructions mainly to retinal ganglion cells. It is not designed to edit the patient’s existing DNA sequence in the way a genome-editing system would. However, that does not mean it carries no genetic or biological risk: the vector can persist in cells, transgene expression may vary, and rare vector-genome integration is a general consideration in gene therapy. The treatment includes a separate control mechanism. According to the ClinicalTrials.gov record: The patient receives a single dose of ER-100. The viral vector remains in the eye. The patient takes oral doxycycline for 56 days. Doxycycline activates OSK expression through an inducible genetic switch. Doxycycline is stopped after eight weeks. The exact numeric vector doses for the dose-escalation groups have not been publicly listed in the main ClinicalTrials.gov record. The trial states that at least two dose levels will be assessed in the open-angle glaucoma cohort. [ClinicalTrials.gov] () What “epigenetic reprogramming” means The epigenome consists of chemical and structural controls that influence which genes are turned on or off. These controls include DNA methylation, chemical changes to histone proteins, and changes in how DNA is packaged. Epigenetic reprogramming does not necessarily change the underlying DNA letters. Instead, it attempts to alter the instructions that determine how the cell reads its existing genome. The theory behind ER-100 is that aging and injury gradually disturb the gene-regulation program that keeps retinal ganglion cells functional. According to this model, some of the damage may be a loss of youthful cellular information rather than irreversible destruction of every component of the cell. OSK is intended to push the cell toward a younger gene-expression state without converting it completely into a stem cell. --- How OCT4, SOX2, and KLF4 are supposed to rejuvenate retinal ganglion cells The three factors are transcription factors. They bind DNA and influence large networks of other genes. OCT4 OCT4 is a major regulator of cell identity and cellular reprogramming. In the original induced-pluripotent-stem-cell experiments, OCT4 helped activate a developmental program that could return adult cells to a stem-cell-like state. In ER-100, the aim is not to drive retinal ganglion cells all the way back to pluripotency. Instead, OCT4 is intended to help reopen or reorganize portions of the gene-regulatory landscape associated with cellular repair and youthfulness. SOX2 SOX2 is another key reprogramming factor. It helps alter chromatin accessibility—the degree to which DNA can be reached by gene-regulating proteins. In retinal ganglion cells, this may help reactivate genes involved in neuronal maintenance, axon growth, stress resistance, and synaptic function. The exact human retinal ganglion cell targets of ER-100 remain unproven. KLF4 KLF4 is involved in cell identity, chromatin regulation, stress responses, and reprogramming. It works together with OCT4 and SOX2 to alter gene-expression networks. The intended result is not simply a lower “epigenetic age” on a laboratory test. The therapeutic claim is that the cells should function better: maintaining axonal transport, resisting injury, and potentially regaining some ability to extend or repair axons. The proposed sequence of events The proposed mechanism can be summarized as: Age or injury alters gene regulation in retinal ganglion cells. These cells become less able to maintain axons and respond to stress. OSK temporarily changes transcription and chromatin organization. DNA methylation patterns and gene expression move toward a more youthful state. The retinal ganglion cells become more resilient or regain some regenerative capacity. Visual signaling improves if enough cells and axons remain connected. The mouse work supports several steps in this chain, but the complete sequence has not been demonstrated in humans. The original Nature study reported that OSK restored youthful DNA methylation patterns and gene-expression profiles in mouse retinal ganglion cells, and that the effect required the DNA-demethylation machinery involving TET1, TET2, and TDG. This is stronger evidence than merely showing that a methylation clock changed, but it still does not prove that aging in human glaucoma is primarily caused by epigenetic information loss. [Nature study] () --- Why ER-100 uses three factors rather than all four Yamanaka factors The original four-factor reprogramming combination is: OCT4 SOX2 KLF4 c-MYC The four-factor combinatio Support the show

    Can Glaucoma Damage Be Reversed? First Human Epigenetic Reprogramming Trial Targets the Optic Nerve

  2. 3d ago

    Why Visual Fields Matter: From Silent Loss to Real-World Function

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/why-visual-fields-matter-from-silent-loss-to-real-world-function Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Why Visual Fields Matter: From Silent Loss to Real-World Function A person can read the smallest line on an eye chart and still have a serious problem with peripheral vision. This is especially common in glaucoma, where vision loss often begins slowly at the sides of the visual field while sharp central vision remains clear. That is why visual field testing matters. It measures not only how clearly a person sees, but also where vision is missing, how sensitive each area is, and whether the pattern is changing over time. In many patients, the test detects functional loss long before they recognize a problem in daily life. () What a Visual Field Test Measures A standard eye chart measures central visual acuity—the ability to see small letters or details directly in front of you. A visual field test measures the wider area that can be seen while the eyes remain fixed on one point. During standard automated perimetry, one eye is tested at a time. The patient looks at a central target and presses a button whenever a flash of light is seen. The machine presents lights of different brightness at many locations and estimates the dimmest light visible at each point. The result is a map of visual sensitivity across the field. () A report may include: A grayscale map, which gives a visual impression of missing or reduced areas. A total deviation map, comparing the result with people of the same age. A pattern deviation map, which helps identify localized defects despite generalized blur from conditions such as cataract or a small pupil. Mean deviation, an age-adjusted summary of overall field loss. More negative values generally indicate more loss. Visual field index, a percentage estimate of remaining age-adjusted field function, with greater emphasis on points near central vision. Pattern standard deviation, which highlights localized, irregular defects. These numbers are useful, but they should not be interpreted alone. The pattern, location, reliability, structural examination of the optic nerve, and the results from previous visits are all important. () Why Patients Often Do Not Notice Visual Field Loss Loss usually begins outside the center In chronic open-angle glaucoma, damage is usually gradual and often begins in the peripheral field. Early disease may produce small blind spots or areas of reduced sensitivity that do not interfere with ordinary tasks. The National Eye Institute notes that early glaucoma often has no symptoms, and many people do not notice that their side vision is changing until the disease is more advanced. () This creates a dangerous mismatch: The optic nerve may already be losing function. The eye chart may still show good central vision. The patient may still feel that vision is “normal.” A visual field test may reveal the problem before everyday symptoms become obvious. The two eyes can compensate for each other Most people do not routinely compare one eye with the other. If a defect affects one eye more than the other, the better eye may help cover the missing area. When the visual fields from both eyes are combined, some defects may be less noticeable than they are during one-eye-at-a-time testing. Research has shown that a person may have measurable defects in each eye while the combined binocular field appears relatively preserved. This is one reason that both monocular results and the likely binocular effect must be considered. () The brain adapts to slowly changing vision A slowly developing blind spot does not produce the same sudden warning as a new loss of vision. Patients may unconsciously turn the head more, scan the environment more often, walk more cautiously, or rely on familiar surroundings. These adjustments can hide the problem until the remaining field becomes much smaller. Adaptation is helpful, but it can also create false reassurance. A person may function adequately in a familiar home while struggling in a crowded store, on an unfamiliar street, in dim lighting, or behind the wheel. How Field Defects Affect Daily Activities The effect of visual field loss depends on where the defect is located, whether it affects one or both eyes, how severe it is, and how quickly it developed. No single field score predicts every real-world ability. For the full table, please open this article on visualfieldtest.com. The relationship is not always predictable. Studies comparing central and far peripheral loss have found that central damage is more closely associated with several measures of quality of life and daily activity, while far peripheral damage may be especially important for stride length, gait variability, and hazard detection. () Driving Driving requires more than reading road signs. It requires: Detecting vehicles, pedestrians, cyclists, and objects approaching from the side Maintaining lane position Responding quickly to unexpected hazards Searching mirrors and intersections Managing glare and low-light conditions Dividing attention between several parts of the visual environment Moderate or severe visual field loss—particularly when it affects both eyes—has been associated with slower responses to road hazards, poorer lane maintenance, greater difficulty driving at night, increased self-restriction, and a greater likelihood of stopping driving. Recent review evidence also links more severe bilateral field loss with poorer driving performance and a higher risk of motor-vehicle collisions. () A visual field test is important for counseling, but it is not the same as a driving test. Safe driving also depends on visual acuity, contrast sensitivity, attention, reaction time, cognition, neck movement, medications, and experience. Driver-licensing standards are jurisdiction-specific, so patients should check their state requirements and ask about a formal driving evaluation when appropriate. State agencies may impose different restrictions or medical-review requirements for people with reduced vision. () Walking, mobility, and falls Peripheral vision helps a person notice objects approaching from the side. Central vision helps identify steps, uneven surfaces, and details in the walking path. Losing either part of the field can cause a person to slow down, shorten steps, widen the base of support, or become more cautious. Research in glaucoma has linked visual field loss with: Greater fear of falling Shorter steps and strides Greater variation from one step to the next Fewer daily steps Difficulty with instrumental activities such as shopping and navigating unfamiliar places Increased mobility restriction Faster rates of binocular visual field loss have also been associated with a greater history of falls, even after considering the existing severity of the field defect. () This is why a patient who says, “I can still see,” should also be asked: Have you stumbled recently? Do you avoid stairs or uneven ground? Do you bump into objects? Do you feel unsafe crossing a street? Have you reduced outdoor activities? Do you need brighter lighting at home? Reading Reading depends on clear central vision, but it also depends on the ability to process several letters at once and move smoothly from one line to the next. Defects near fixation or in the central visual field can reduce the visual span—the amount of text recognized during one glance. People with bilateral glaucoma may read more slowly, lose their place, skip lines, struggle with small or low-contrast print, and become tired during prolonged reading. These problems may occur even when visual acuity remains relatively good. In one study, glaucoma was associated with slower oral and silent reading, and sustained silent reading was particularly affected. () Reading difficulty is therefore not always corrected by stronger glasses. Helpful strategies may include better lighting, larger print, higher contrast, magnification, electronic reading devices, and vision rehabilitation. Visual Fields and Quality of Life Clinical measurements and patient experience are related, but they are not identical. Two people with similar visual field scores may have very different lifestyles, work demands, home environments, coping strategies, and levels of disability. Patient-reported measures Several questionnaires help measure the effect of visual loss on daily life: The Glaucoma Quality of Life-15 questionnaire focuses on central and near vision, peripheral vision, glare and dark adaptation, and outdoor mobility. The National Eye Institute Visual Function Questionnaire-25 covers areas such as general vision, near and distance activities, driving, social functioning, role difficulties, dependence, and mental health. General disability and activity questionnaires may assess walking, shopping, reading, household activities, and independence. Studies consistently show that quality of life tends to worsen as binocular visual field loss becomes more severe. Faster visual field decline is also associated with worse later vision-related quality of life, even when two patients have similar amounts of damage at a single visit. () Objective functional measures Research can also measure function directly, using: Reading speed Number of daily steps Walking speed and stride variability Simulated shopping or object-finding tasks Falls Driving restriction or driving c Support the show

    Why Visual Fields Matter: From Silent Loss to Real-World Function

  3. 5d ago

    Do More Data Points Reveal Clearer Trends? Power and Noise in VF Progression

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/do-more-data-points-reveal-clearer-trends-power-and-noise-in-vf-progression Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Do More Data Points Reveal Clearer Trends? Power and Noise in Visual Field Progression Introduction In glaucoma, visual field testing is used to determine whether vision is stable or gradually worsening. The challenge is that each test contains some noise. Attention, fatigue, learning, cataract, dry eye, fixation, and the patient’s underlying level of damage can all affect the result. Testing more often usually makes a true trend easier to recognize. However, the benefit is not proportional. Moving from one test per year to two often provides a meaningful gain. Moving from two to three tests per year may help, but the additional benefit is smaller. Testing too often can also create more apparent “changes” that later disappear, especially when statistical thresholds are applied repeatedly. The practical goal is therefore not to collect the largest possible number of visual fields. It is to collect enough high-quality tests, spaced appropriately, to detect clinically important progression without creating unnecessary burden or false alarms. Current glaucoma guidance supports at least annual testing for established glaucoma, with more frequent testing during the first two years after diagnosis or when the risk of rapid progression is high. () Why visual field progression is difficult to detect A visual field test measures light sensitivity at many locations. The result is not a direct photograph of the optic nerve. It is a behavioral measurement that depends on the patient noticing and responding to visual stimuli. A simple way to describe a visual field series is: > Observed result = true visual function + measurement noise The true glaucoma signal may be a gradual decline of only a fraction of a decibel per year, while the variation between individual tests can be several decibels at some locations. Test–retest variability tends to be greater in eyes with more advanced damage, lower sensitivity, peripheral defects, and certain defect patterns. () Mean deviation Mean deviation is a single summary number describing the overall visual field compared with an age-adjusted normal field. A negative number indicates loss; a more negative number indicates greater overall loss. Mean deviation is useful because it averages information across the field and is relatively easy to follow over time. A clinician can plot mean deviation against time and calculate a slope, such as: −0.3 decibels per year: slow change −1.0 decibel per year: moderate change −2.0 decibels per year: rapid change However, mean deviation can miss localized progression if the damaged area is small. It can also be influenced by diffuse factors such as cataract or other media opacity. () Pointwise slopes Pointwise linear regression evaluates each test location separately. It can show that a particular cluster of locations is worsening at, for example, −1.2 decibels per year. This approach can detect localized or paracentral progression that is diluted within a whole-field average. Its disadvantages are that individual locations are noisier than the overall mean, many locations are tested simultaneously, and the chance of at least one apparently significant result increases as more locations and more visits are examined. () How increasing test frequency improves signal-to-noise For a trend analysis, additional tests help in two ways: They provide more observations, reducing uncertainty about the estimated slope. They show whether a change is persistent, rather than a single unusually poor result. The timing of the tests also matters. A slope is estimated more precisely when tests are distributed across a longer time span. Three tests performed within a few weeks provide a better estimate of short-term repeatability, but three tests spaced over a year provide more information about long-term decline. This is why two baseline tests close together can be useful for learning and repeatability, while later tests should usually be spread across the follow-up period. The European Glaucoma Society emphasizes that determining an individual rate of progression generally requires at least two years and enough reliable visual fields. () Simulation evidence: the largest gains occur early Mean deviation: one versus two versus three tests per year Wu and colleagues used real visual field variability from 1,072 eyes and reconstructed visual field series through computer simulation. Their analysis required two baseline tests and a confirmatory test before progression was counted. The estimated time required to detect progression in 80% of eyes was: () For the full table, please open this article on visualfieldtest.com. These results show two important principles: Increasing testing from once to twice yearly produced a substantial improvement. Increasing testing from twice to three times yearly produced a smaller improvement. For a rapidly progressing eye losing −2.0 decibels per year, moving from annual to six-monthly testing shortened modeled detection time by approximately 0.9 years. Moving from six-monthly to four-monthly testing shortened it by only about 0.3 years. For a slower eye losing −0.5 decibels per year, even three tests per year required approximately five years to achieve 80% detection power. More frequent testing helps, but it cannot completely overcome a very small signal or high measurement variability. () An earlier practical analysis reached a similar conclusion. For an eye with average variability, approximately three tests per year were estimated to be needed to detect a four-decibel mean deviation decline over two years with 80% power. The authors recommended six reliable examinations during the first two years to establish a baseline and identify unusually rapid progression. () Pointwise slopes: greater sensitivity, but more false alarms Gardiner and Crabb developed a “virtual eye” simulation in which a test location was either stable or deteriorating at a known rate. When a location was truly worsening at 2 decibels per year, more frequent testing allowed pointwise linear regression to identify progression sooner. But when the simulated location was stable, increasing test frequency also increased the number of series falsely labeled as progressing during the early years. Their conclusion was that three tests per year provided a practical compromise between sensitivity and specificity for pointwise linear regression. () This is an important qualification: more data improve the chance of detecting a real trend, but they also create more opportunities to observe an unusual sequence of results. Statistical methods therefore need confirmation rules and appropriate thresholds. What real-world visual field series show The Advanced Glaucoma Intervention Study Nouri-Mahdavi and colleagues analyzed 468 eyes from the Advanced Glaucoma Intervention Study. They compared the original, more frequent visual field series with a version in which approximately half of the later tests had been removed. The high-frequency series had a median interval of about six months, compared with approximately 11.3 months in the lower-frequency series. Progression based on mean deviation was detected in: 43.6% of eyes with the more frequent series 34.2% of eyes with the less frequent series Using pointwise linear regression, progression was detected in: 39.5% of eyes with the more frequent series 35.7% of eyes with the less frequent series The hazard of detecting mean deviation progression was 1.69 times higher with more frequent testing. For pointwise linear regression, the hazard was 1.52 times higher. The benefit was particularly evident with global mean deviation analysis. () This real-world analysis supports the simulation findings: six-monthly testing generally detects progression earlier than approximately annual testing, but the gain is larger for mean deviation than for pointwise slopes. Real-world testing in the United States A more recent study used real-world visual field variability from the Duke Glaucoma Registry and simulated progression at testing frequencies observed in a large United States insured population. For modeled progression rates of −0.5 or −1.0 decibels per year, the time required to detect progression in 80% of eyes was estimated as follows: () For the full table, please open this article on visualfieldtest.com. These numbers are modeled estimates, not a prediction for every patient. They nevertheless demonstrate how infrequent testing can delay recognition of progression for many years. The study also found that more than three-quarters of patients in the underlying nationwide cohort received fewer than one visual field test per year. () Frontloading tests A 2024 simulation study used progression rates and baseline characteristics from Swedish and Canadian glaucoma cohorts. It compared one visual field test per visit with a “frontloaded” strategy involving two tests per visit. When visits occurred every six months, frontloading detected progression approximately one to one-and-a-half years earlier in many scenarios. At four years, it increased the proportion of detected progressors by roughly 27% to 32%, depending on the amount of missing data. The simulated eyes also had less visual field loss when progression was detected. () Front Support the show

    Do More Data Points Reveal Clearer Trends? Power and Noise in VF Progression

  4. Aug 4

    Patient Education to Improve VF Performance and Reduce Anxiety

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/patient-education-to-improve-vf-performance-and-reduce-anxiety Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Patient Education to Improve Visual Field Test Performance and Reduce Anxiety Visual field testing—also called perimetry—is essential for detecting and monitoring glaucoma, optic nerve disease, retinal disease, and some neurological conditions. During standard automated perimetry, one eye is tested at a time while the patient looks at a central target and presses a button whenever a light is seen in the surrounding area. The test estimates how sensitive different parts of the visual field are. () Because the test depends on attention, understanding, fixation, and timely responses, patient education can directly affect the quality of the result. Anxiety, fatigue, unfamiliarity, incorrect responses, and difficulty maintaining fixation may lead to unreliable findings or unnecessary repeat testing. In a prospective study, higher pre-test anxiety was associated with greater visual field unreliability, while patients who had completed more than 10 previous tests reported substantially less anxiety. () Why Patient Education Matters A patient does not need to see every light to perform well. The goal is to respond accurately to the lights that are visible and to avoid pressing the button simply because a light is expected. Education helps patients understand that: The lights vary in brightness. Some lights will be too dim to see. Missing occasional lights is expected. The patient should look at the central fixation target rather than chase peripheral lights. Blinking is allowed. A short pause can usually be requested if the patient becomes tired or uncomfortable. The test is not an examination that can be “failed” through one or two missed responses. A learning curve is common. Repeated testing can improve attention, response timing, and understanding of the procedure, although a better result after practice does not necessarily mean that the eye itself has improved. () Educational Interventions That Improve Performance Short Educational Videos A three- to five-minute video can show the patient what the instrument looks like, where to look, how the button works, and what the flashes will feel like during the test. A randomized study of 244 patients undergoing their first automated visual field test used a 4.5-minute educational video. Reliable results in both eyes were obtained in: 75.9% of patients who watched the video 61.4% of patients who received usual instruction without the video This was an absolute improvement of 14.5 percentage points. The main benefit occurred in the second eye tested: reliability was 86.6% with the video versus 73.5% without it. () A later quality-improvement audit used a 4.5-minute video in patients with no previous experience of standard automated perimetry. Reliability increased from 66.7% before the intervention to 87.5% afterward, an improvement of 20.8 percentage points. The video explained fixation, blinking, the changing brightness of the lights, and when to request a pause. () The video should be: Short enough to watch immediately before testing Available in the patient’s preferred language Demonstrated from the patient’s viewpoint Focused on behavior rather than disease terminology Followed by an opportunity to ask questions Interactive Demonstrations An interactive demonstration can be more effective than spoken instructions alone because it allows the patient to see and rehearse the exact task. A useful demonstration may include: A central fixation target A simulated peripheral flash A button response Examples of lights that are easy to see and lights that are barely visible A brief example showing that the patient should not move the eyes toward the flash A demonstration of normal blinking and pausing Direct research on a separate interactive perimetry simulator is still limited. However, studies comparing video and spoken instruction consistently suggest that visual explanation improves understanding and confidence. In one prospective study of 120 patients with no previous experience of the test, patients receiving video instruction had better reported relaxation and motivation than those receiving verbal instruction alone. () Teach-Back and Short Practice Questions After a video or demonstration, the technician can ask the patient to explain the procedure in their own words. This is called teach-back. Useful questions include: “Where will you look during the test?” “When should you press the button?” “What should you do if you do not see a light?” “Are you allowed to blink?” “What should you do if you become tired?” In the 2022 educational-video audit, patients completed a seven-question assessment. Among patients with unreliable tests, 76.9% scored fewer than four correct answers. Every patient who scored more than four correct answers had a reliable result. This finding shows a strong association between understanding and test quality, although it does not prove that the quiz alone caused the improvement. () Practice Tests A short practice exercise can reduce the unfamiliarity that makes the first test stressful. A practice exercise should be clearly labeled as training only, not as a clinical result. In a study of 55 healthy adults with no previous perimetry experience, the median test duration decreased from: 5.7 minutes during the first test 5.3 minutes during the second test False-negative responses also decreased from a median of 2% to 0%. Sensitivity increased during the second test, particularly in peripheral locations. () Practice should be brief. A full additional threshold test may create fatigue and may alter the patient’s performance through learning. For most patients, a short demonstration or practice block is preferable to repeatedly performing a complete clinical test before the actual measurement. Combined Video and Verbal Instruction Video appears to work best when it reinforces, rather than replaces, a clear explanation from the technician. In a study of 90 patients, three instruction methods were compared: Verbal instruction alone Video instruction alone Video followed by verbal instruction The combined video-and-verbal approach resulted in the fewest repeat tests. Both video instruction and combined instruction produced more reliable fields than verbal instruction alone. () The technician should use a consistent script. Instructions that are too strict may cause patients to withhold responses; instructions that encourage excessive guessing may increase false-positive responses. The patient should follow the instructions for the specific instrument and testing algorithm being used. Quantified Effects on Reliability and Test Duration The available studies show a clearer improvement in reliability than in test duration. For the full table, please open this article on visualfieldtest.com. Important Limitations These percentages should not be combined as if they came from one large trial. The studies used different: Patient populations Visual field instruments Testing algorithms Definitions of a “reliable” test Instruction methods Study designs Some studies were randomized, while others were audits or before-and-after comparisons. Reliability indices such as fixation losses, false-positive responses, and false-negative responses are useful, but they should not be interpreted in isolation. Modern interpretation also considers the gaze trace, the pattern of loss, test duration, disease severity, and whether the result makes clinical sense. () A Practical Structured Coaching Protocol A clinic can provide structured coaching in approximately five to eight minutes. Step 1: Set Expectations Use simple language: > “This test measures how sensitive different parts of your vision are. You will not see every light. Missing some lights is normal.” This reduces the fear that a patient must respond perfectly. Step 2: Show the Procedure Use a video, tablet demonstration, or printed illustration to show: The central fixation target The surrounding flashes The response button The covered eye How the patient should sit How the technician monitors fixation Step 3: Demonstrate the Correct Response Tell the patient: Look steadily at the central target. Press only when a light is seen. Do not move the eyes toward the light. Blink normally. Do not try to predict when the next flash will appear. Ask for a pause if needed. The exact response instruction should match the instrument’s protocol. Step 4: Use Teach-Back Ask the patient to explain the procedure. Correct misunderstandings before testing begins. Step 5: Offer a Brief Practice A short non-diagnostic practice sequence can familiarize the patient with the button and the changing brightness of the lights. The practice result should not be used as the patient’s clinical baseline. Step 6: Use Neutral Support During Testing The technician should monitor the patient’s position, alertness, and fixation without repeatedly giving performance-related comments. Overly frequent prompts may distract the patient or alter responses. A standardized script and consistent technician approach are preferable because technician instructions can influence perimetry results. () In-Clinic Tutoring Versus Application-Based Home Modules What In-Clinic Tutoring Does Best In-clinic tutoring is strongest when: The patient is taking the test for the first time. T Support the show

    Patient Education to Improve VF Performance and Reduce Anxiety

  5. Aug 2

    Who Should Get Visual Field Testing? A Population-Based Framework

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/who-should-get-visual-field-testing-a-population-based-framework Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Who Should Get Visual Field Testing? A Population-Based Framework Visual field testing measures how well a person sees across the central and peripheral parts of the visual field. It is especially important because many eye and brain disorders damage peripheral vision gradually, without causing obvious symptoms at first. However, routine visual field testing is not necessary for every healthy, asymptomatic adult. The highest value comes from testing people whose examination, medical history, medication use, or disease pattern creates a meaningful risk of developing or worsening field loss. This targeted approach helps detect silent damage while limiting false-positive results, unnecessary anxiety, and avoidable testing. What Visual Field Testing Detects Most clinical visual field tests use automated static threshold perimetry. One eye is tested at a time while the patient looks at a central target and presses a button whenever a spot of light is seen. The test can identify: Peripheral blind spots caused by glaucoma Central or paracentral defects affecting reading or fixation Bitemporal defects associated with pituitary or other chiasmal disease Altitudinal defects associated with ischemic optic neuropathy Enlargement of the blind spot associated with papilledema Concentric peripheral loss caused by some toxic retinal disorders Hemifield loss after stroke or damage to the visual pathways Visual field testing is different from a visual acuity test. A person may still read the eye chart well while having important peripheral field loss. The two eyes also overlap, allowing one eye to compensate for defects in the other. Because visual field testing depends on attention, learning, fatigue, and response consistency, one abnormal result should usually be confirmed unless the pattern is clearly urgent. National Institute for Health and Care Excellence glaucoma guideline () The Population-Based Principle: Targeted Testing Rather Than Universal Screening The United States Preventive Services Task Force has found insufficient evidence to recommend routine population-wide screening for primary open-angle glaucoma in asymptomatic adults. This does not mean that visual field testing is unhelpful. Rather, it means that testing is more useful when directed toward people with identifiable risk factors or suspicious findings. United States Preventive Services Task Force recommendation () A comprehensive eye examination is still important, particularly as people get older or develop medical risk factors. The American Academy of Ophthalmology recommends a baseline comprehensive eye examination around age 40, with follow-up based on individual risk. Visual field testing should then be added when there is a suspicious optic nerve, elevated intraocular pressure, a relevant medication exposure, visual symptoms, or a disorder affecting the optic nerve or brain. American Academy of Ophthalmology glaucoma screening information () The groups most likely to benefit from routine or repeated testing are: Glaucoma suspects People with ocular hypertension People with established glaucoma Patients with neuro-ophthalmic disease Patients taking medications that can injure the retina or optic nerve Evidence on Asymptomatic Visual Field Loss Glaucoma may be advanced before a patient notices it Glaucoma usually develops slowly. Early defects often occur outside the central line of sight, and the brain can partially compensate for missing information. As a result, patients may not notice a problem until the disease is advanced. Population-based research has found that approximately half of people with manifest glaucoma in developed countries may be unaware that they have the disease. In a screening cohort from the Early Manifest Glaucoma Trial, one-third of people with previously undetected glaucoma had advanced visual field loss in at least one eye. Early Manifest Glaucoma Trial population screening study () The risk is not limited to people with poor visual acuity. A patient can have good central vision and still have loss in the upper, lower, nasal, or temporal field. Visual field loss has also been associated with reduced mobility, falls, and lower quality of life in population studies. Rotterdam Study of visual field loss and daily functioning () Why asymptomatic loss matters clinically Detecting field loss before a patient notices it can: Confirm that structural changes are functionally important Establish the stage of glaucoma Identify patients who need pressure-lowering treatment Reveal progression before a major daily-life problem develops Prompt neurological imaging when the pattern is not typical for glaucoma Trigger medication review when toxicity is suspected The goal is not simply to find an abnormal test. The goal is to find a repeatable, clinically meaningful change that alters care. Glaucoma Suspects A glaucoma suspect may have one or more of the following: Elevated intraocular pressure A large or asymmetric optic nerve cup Suspicious thinning of the retinal nerve fiber layer A disc hemorrhage A suspicious or borderline visual field A strong family history of glaucoma Thin central corneas Myopia, pseudoexfoliation, pigment dispersion, or other risk factors A person can be a glaucoma suspect even when the visual field is normal. In this situation, the field provides an important functional baseline against which later tests can be compared. Who among glaucoma suspects benefits most? Visual field testing is particularly valuable when a patient has: A suspicious optic nerve appearance Asymmetry between the two optic nerves Retinal nerve fiber layer or ganglion cell thinning on imaging Repeatedly elevated intraocular pressure A first-degree relative with glaucoma A disc hemorrhage A thin central cornea High myopia A previous borderline or abnormal field A visual complaint that is not explained by glasses, cataract, or retinal disease The American Academy of Ophthalmology recommends that observed primary open-angle glaucoma suspects generally be reassessed at least every 12 to 24 months, with more frequent assessment when several risk factors are present. American Academy of Ophthalmology Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern () How visual field results change care in a glaucoma suspect Normal and stable field: continued observation may be appropriate. One questionable abnormal field: repeat the test, check reliability, and compare it with the optic nerve and imaging. Repeatable glaucomatous pattern: the diagnosis may change from “suspect” to glaucoma. Field loss that does not match the optic nerve: consider a neurological or retinal cause. Paracentral loss: closer monitoring is often needed because central function may be threatened even when the overall field appears mild. A visual field should therefore be interpreted together with intraocular pressure, optic nerve examination, retinal imaging, corneal thickness, and the patient’s history. People With Ocular Hypertension Ocular hypertension means that the pressure inside the eye is consistently elevated, but there is not yet definite optic nerve damage or visual field loss. Many people with ocular hypertension never develop glaucoma. The Ocular Hypertension Treatment Study found that about 9.5% of untreated participants developed glaucoma over five years, compared with about 4.4% of participants who received pressure-lowering treatment. Risk was not equal among all participants. Higher pressure, older age, larger cup-to-disc ratio, and thinner central corneas increased the likelihood of conversion. American Academy of Ophthalmology EyeWiki: Ocular Hypertension () Why visual fields are still needed when the field is initially normal A normal field helps confirm that elevated pressure has not yet caused detectable functional damage. Repeated testing can later identify conversion from ocular hypertension to glaucoma. For a low-risk patient with normal optic nerves and stable pressure, visual field testing does not need to be performed at every visit. In contrast, a patient with very high pressure, a thin central cornea, a strong family history, older age, suspicious imaging, or a disc hemorrhage generally deserves closer surveillance. The National Institute for Health and Care Excellence recommends reassessment approximately every 18 to 24 months for treated ocular hypertension with controlled pressure and no detected conversion, but approximately every 6 to 12 months when conversion is uncertain or pressure control is inadequate. These intervals are guides rather than rigid rules. National Institute for Health and Care Excellence reassessment guidance () Practical approach for ocular hypertension A reasonable approach is: Obtain a reliable baseline visual field, often repeating it to confirm consistency. Document the optic nerve and retinal nerve fiber layer. Measure central corneal thickness. Estimate conversion risk using the full clinical picture. Repeat the field approximately every 12 to 24 months if risk is low and all findings remain stable. Test every 6 to 12 months when risk is moderate or high. Repeat sooner when pressure rises, the optic nerve changes, or a disc hemorrhage appears. Established Glaucoma Patients with established glaucoma benefit most consist Support the show

    Who Should Get Visual Field Testing? A Population-Based Framework

  6. Aug 1

    Real-World Evidence: Outcomes When Testing Frequency Increases

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/real-world-evidence-outcomes-when-testing-frequency-increases Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Real-World Evidence: Outcomes When Visual Field Testing Frequency Increases Visual field testing, also called perimetry, measures areas of vision that a person can and cannot see. It is especially important in glaucoma, because damage to the optic nerve may progress without noticeable symptoms until substantial vision has been lost. The practical question is not simply whether more tests produce more data. It is whether more frequent testing leads to earlier detection of true progression, better treatment decisions, preserved vision, and acceptable safety and workload. The current evidence suggests that increasing testing frequency usually improves the speed and precision of detecting visual field change. However, there is not yet strong proof that more frequent testing alone prevents blindness or improves quality of life. Evidence for home visual field testing used alongside clinic care is encouraging but still based mainly on small, selected studies rather than large comparative outcome trials. Key Findings at a Glance Clinic-based testing every six months detects progression earlier than approximately yearly testing, particularly when overall visual field trends are analyzed. In a large United States claims cohort, the median testing frequency was only 0.63 visual field tests per year, and more than three-quarters of patients had fewer than one test per year. Home testing can provide weekly or monthly measurements, reduce measurement noise, and sometimes identify a concerning change before the next planned clinic visit. Adherence is the main limitation. Short studies often report good participation, but longer studies show that testing frequency commonly declines over time. More frequent testing also produces more apparent progression signals, some of which later disappear. Confirmation rules are therefore essential. Direct evidence that increased testing changes long-term visual outcomes remains limited. Home testing should generally be treated as an adjunct to clinical examination, not a replacement for eye pressure measurement, optic nerve examination, imaging, and standard clinic-based perimetry. What Guidelines Recommend The European Glaucoma Society notes that there is still no definitive evidence showing which combination of tests or testing frequency produces the best patient outcomes at a sustainable cost. Nevertheless, it recommends obtaining enough early visual field measurements to estimate the individual rate of change. Newly diagnosed patients are often recommended to have standard automated perimetry approximately three times per year during the first two years, after which the schedule can be tailored to disease severity and observed progression. European Glaucoma Society guidelines The World Glaucoma Association similarly recommends an intensive early series in people at risk of visual disability. It suggests that lower-risk patients may later be tested about once a year, while higher-risk patients may need testing twice a year or more often if progression is suspected. World Glaucoma Association consensus These recommendations are based largely on the need to establish a reliable baseline and identify fast progression early. They should not be interpreted as a requirement for every patient to have the same schedule. Testing frequency should reflect: Existing visual field damage Rate of previous change Age and expected lifetime risk Whether the patient has only one useful eye Pressure control Optic nerve or retinal nerve fiber layer changes Presence of optic nerve hemorrhage Test reliability Patient ability to attend or complete testing How Often Are Patients Actually Tested? United States nationwide data A study of 380,029 people with open-angle glaucoma found that: 8.8% had no visual field test during the study period. 68.2% received fewer than 0.9 tests per year. Only 0.8% received at least 2.1 tests per year. The median testing frequency was 0.63 tests per year. The authors concluded that more than 75% of the population had fewer than one visual field test per year, which is below the frequency commonly recommended for many patients under active glaucoma monitoring. This study described healthcare delivery; it did not prove that increasing frequency would prevent vision loss. United States nationwide glaucoma cohort English hospital eye-service data A large electronic medical record audit evaluated 602,439 visual field records from 73,994 people across five glaucoma clinics in England. Among 25,760 patients with repeatable visual field loss: The median interval between visual field tests was 11.2 months. Approximately 4.6% of tests were classified as unreliable using the study’s reliability measure. The median rate of visual field change was approximately −0.21 decibels per year. About 24% of patients had advanced field loss at presentation. Differences in testing intervals and reliability were observed between clinics. This type of registry evidence is valuable because it reflects routine care rather than a highly controlled clinical trial. It also demonstrates how electronic records can monitor service quality, identify patients at risk, and measure whether a clinic is delivering testing consistently. English glaucoma visual field audit Outcomes When Clinic-Based Testing Frequency Increases Earlier detection of progression One of the clearest real-world analyses came from the Advanced Glaucoma Intervention Study. Researchers compared the original series of visual fields with a reduced-frequency series created by removing approximately every other follow-up test. The higher-frequency series had a median of 20 tests, compared with 12 tests in the lower-frequency series. Using a global measure called mean deviation: Progression was detected in 43.6% of eyes with the higher-frequency data. Progression was detected in 34.2% of eyes with the lower-frequency data. The higher-frequency series was about 69% more likely to identify progression using the mean deviation analysis. Using a point-by-point analysis, progression was detected in 39.5% of eyes with higher-frequency data versus 35.7% with lower-frequency data. The higher-frequency series was still more likely to detect progression, although the difference was smaller. Advanced Glaucoma Intervention Study frequency analysis This is important, but it must be interpreted correctly. The study showed that more frequent testing detects statistical progression sooner. It did not show that the additional tests themselves slowed disease or preserved vision. It was also not a randomized trial of two separate monitoring programs; the lower-frequency series was created by deleting tests from an existing dataset. Six-monthly testing may be a practical compromise A longitudinal cohort study used data from 1,072 eyes of 665 patients to model how quickly different rates of glaucoma progression could be detected. For eyes losing approximately 2 decibels per year, a progression signal could be detected with 80% statistical power after approximately: 3.3 years with yearly testing 2.4 years with testing twice per year 2.1 years with testing three times per year For slower loss of approximately 0.5 decibels per year, detection took approximately: 7.3 years with yearly testing 5.7 years with twice-yearly testing 5.0 years with testing three times per year The improvement from yearly to twice-yearly testing was larger than the improvement from twice-yearly to three-times-yearly testing. The authors concluded that two reliable baseline tests followed by testing approximately every six months, with confirmation of suspected progression, may offer a practical balance between speed and burden. Longitudinal cohort study of visual field testing frequency Personalized schedules may be more efficient than fixed schedules A separate analysis using data from the Advanced Glaucoma Intervention Study and the Collaborative Initial Glaucoma Treatment Study evaluated a personalized testing model. The model increased testing when the patient’s previous results suggested a higher likelihood of progression and reduced testing when the disease appeared stable. Compared with a fixed yearly schedule, the model: Detected progression 57% sooner. Improved progression-detection efficiency by 29%. Did not require more visual field tests overall. This was a model based on previous clinical trial data rather than a prospective implementation study. It supports a risk-based approach, rather than testing every patient at the same frequency. Personalized glaucoma monitoring schedule study Frontloading tests may increase information without adding visits An emerging clinic-based strategy is to perform two visual field tests per eye during the same visit and use their average. A 2025 prospective study found that this “frontloaded” approach reduced variability in global and point-by-point measurements compared with using one test per visit. The average rate of progression was similar, but the estimates were more precise. Frontloaded visual field testing study This may be useful for patients who cannot perform home testing or who have difficulty attending additional appointments. Do More Tests Lead to More Treatment Changes? The clinical pathway A confirmed visual field decline may lead an eye specialist t Support the show

    Real-World Evidence: Outcomes When Testing Frequency Increases

  7. Jul 31

    Oxidative Stress Pathways from High Sugar Exposure: Nrf2, Mitochondria, and RGC Survival

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/oxidative-stress-pathways-from-high-sugar-exposure-nrf2-mitochondria-and-rgc-survival Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Oxidative Stress Pathways from High Sugar Exposure: Nrf2, Mitochondria, and Retinal Ganglion Cell Survival Introduction High sugar exposure is often discussed as though it has one simple effect on the eye. The biology is more complicated. In experimental studies, elevated D-glucose can increase reactive oxygen species, disrupt mitochondrial energy production, alter antioxidant defenses, activate retinal glial cells, and promote retinal ganglion cell injury. Most of the evidence comes from two types of research: Cell-culture studies, in which retinal cells are exposed to glucose concentrations commonly ranging from 20 to 40 millimoles per liter, sometimes for several days. Diabetic animal models, in which chronic hyperglycemia occurs together with vascular dysfunction, inflammation, lipid abnormalities, advanced glycation products, and tissue hypoxia. These models do not prove that one high-sugar meal directly kills retinal ganglion cells. They do, however, support a biological pathway in which persistent or repeated hyperglycemia increases oxidative pressure and reduces the ability of ocular cells to recover. The most consistent model is: > High glucose → increased reactive oxygen and nitrogen species → mitochondrial stress and impaired energy production → inadequate nuclear factor erythroid 2-related factor 2 antioxidant activity → inflammation, glial reactivity, and retinal ganglion cell apoptosis. The strength of each link varies by cell type, glucose concentration, exposure time, and whether the experiment involves diabetes, glaucoma-related stress, or isolated high glucose. --- The central redox system: reactive oxygen species and nuclear factor erythroid 2-related factor 2 Reactive oxygen species are chemically reactive oxygen-containing molecules. In small amounts, they participate in normal cell signaling. When their production exceeds antioxidant capacity, they can oxidize proteins, membrane lipids, mitochondrial DNA, and other cellular structures. The main protective pathway discussed in this context is controlled by nuclear factor erythroid 2-related factor 2, commonly called Nrf2. Under resting conditions, Nrf2 is held in the cytoplasm by Kelch-like ECH-associated protein 1, or Keap1, which promotes its degradation. When oxidative stress is sensed, Nrf2 can stabilize, move into the nucleus, and stimulate antioxidant-response genes. These include genes involved in glutathione production, superoxide removal, hydrogen peroxide breakdown, thioredoxin recycling, and detoxification. () Important Nrf2-regulated defenses in retinal cells include: Glutamate-cysteine ligase, which supports glutathione production Superoxide dismutase 2, a mitochondrial antioxidant enzyme Catalase Thioredoxin Heme oxygenase-1 NAD(P)H quinone oxidoreductase 1 A key finding across the literature is that high glucose does not always completely turn off Nrf2. Instead, the response may be delayed, transient, cell-specific, or insufficient for the amount of oxidative stress produced. --- How high glucose increases oxidative stress in ocular cells Increased metabolic pressure Retinal neurons and glial cells are metabolically active. When excess glucose enters the cell, more carbon is directed through glycolysis and mitochondrial energy pathways. This can increase the supply of reducing equivalents to the mitochondrial respiratory chain. If electron transport becomes overloaded or poorly coordinated, electrons can leak and generate superoxide. Experimental retinal studies have also identified non-mitochondrial contributors, including: Activation of nicotinamide adenine dinucleotide phosphate oxidase Increased inflammatory signaling through nuclear factor kappa B Thioredoxin-interacting protein induction Nitric oxide and reactive nitrogen species production Disruption of glutathione and antioxidant enzyme systems In Müller glial cells, high glucose increased reactive oxygen species within hours and increased reactive nitrogen species even earlier. The same study found increased nuclear factor kappa B signaling and increased inducible nitric oxide synthase, linking redox imbalance to inflammation. () Oxidative stress can become self-reinforcing Mitochondria are both a source and a target of reactive oxygen species. Once mitochondrial proteins, membranes, or mitochondrial DNA are damaged, the respiratory chain may become less efficient. This can produce still more oxidant leakage, creating a feedback loop: > High glucose → mitochondrial stress → more reactive oxygen species → further mitochondrial damage. In Müller cells, high glucose increased mitochondrial superoxide, disrupted mitochondrial membrane potential, and increased the mitochondrial localization of thioredoxin-interacting protein. These changes were associated with mitochondrial dysfunction and impaired mitochondrial quality control. () --- Evidence for glucose-induced mitochondrial dysfunction Müller glial cells One of the clearest mitochondrial studies used a rat Müller cell line exposed to 30 millimoles per liter glucose for seven days. High glucose caused: Mitochondrial fragmentation Greater variation in mitochondrial membrane potential Lower basal and maximal oxygen consumption Lower extracellular acidification Cytochrome c release Increased apoptosis These findings are important because they connect mitochondrial structural changes with functional failure and cell death rather than merely showing an increase in a laboratory oxidative-stress marker. () A related study found that high glucose increased thioredoxin-interacting protein, mitochondrial superoxide, and mitochondrial membrane-potential abnormalities in rat Müller cells. The changes were accompanied by impaired mitophagy, the process that removes damaged mitochondria. () More recent work suggests that mitochondrial remodeling is not always the same in every stage of disease. Under diabetic conditions, Müller cells may initially use mitochondrial fragmentation as an adaptive response to remove damaged segments. In more advanced neurodegeneration, mitochondrial hyperfusion and defective turnover may develop instead. This means that mitochondrial shape alone cannot be interpreted without considering exposure duration and disease stage. () Retinal ganglion cells Retinal ganglion cells are especially vulnerable to mitochondrial stress because they have long axons and substantial energy requirements. In high-glucose retinal ganglion cell models, investigators have reported: Increased reactive oxygen species Loss or abnormality of mitochondrial membrane potential Cytochrome c release Reduced antioxidant enzyme activity Increased B-cell lymphoma-2-associated X protein and caspase signaling Increased terminal deoxynucleotidyl transferase dUTP nick-end labeling, a marker of DNA fragmentation Reduced cell survival In one study, L-carnitine, a mitochondrial-supporting molecule, reduced glucose-induced reactive oxygen species and lipid peroxidation. It also restored mitochondrial membrane potential, reduced cytochrome c release, lowered caspase-9 and caspase-3 activation, and shifted the B-cell lymphoma-2-associated X protein to B-cell lymphoma-2 balance toward cell survival. () A 2024 study using a retinal precursor cell model and diabetic mice found that high glucose or diabetes was associated with mitochondrial dysfunction, reactive oxygen species production, abnormal antioxidant protein expression, and retinal ganglion cell apoptosis. Increasing DJ-1, a protein involved in mitochondrial protection and redox control, improved mitochondrial function and reduced oxidative injury. () Mitochondrial DNA damage Mitochondrial DNA is located close to the respiratory chain and has less protection than nuclear DNA. A recent retinal ganglion cell study reported that high glucose was associated with mitochondrial structural abnormalities, increased reactive oxygen species, abnormal mitochondrial membrane potential, lower oxygen consumption, lower adenosine triphosphate production, and mitochondrial DNA damage. The authors also observed reduced expression of proteins involved in DNA damage repair. () These results support a model in which mitochondrial damage is not simply a consequence of apoptosis. It may occur early enough to contribute to the decision of a retinal ganglion cell to enter an apoptotic pathway. --- Evidence for impaired or inadequate Nrf2 antioxidant responses A transient Nrf2 failure in Müller cells A detailed time-course study exposed primary rat Müller cells to 25 millimoles per liter glucose for one to 48 hours. The findings show why the phrase “Nrf2 impairment” needs to be used carefully: Reactive oxygen species increased from approximately 12 to 48 hours. Reactive nitrogen species rose earlier. Nrf2 protein and nuclear Nrf2 temporarily decreased after approximately three hours. Glutamate-cysteine ligase, superoxide dismutase 2, and thioredoxin messenger RNA fell during the early exposure period. Glutathione remained low even after some Nrf2 measures recovered. Nrf2 and several antioxidant genes increased later, suggesting a delayed compensatory response. Thus, high glucose produced an early window in which oxidative stress increased while the Nrf2 antioxidant program was temp Support the show

    Oxidative Stress Pathways from High Sugar Exposure: Nrf2, Mitochondria, and RGC Survival

  8. Jul 29

    Aspartame, Sucralose, Saccharin, and Stevia: Comparative Mechanistic Plausibility in Glaucoma

    This audio article is from VisualFieldTest.com. Read the full article here: https://visualfieldtest.com/en/aspartame-sucralose-saccharin-and-stevia-comparative-mechanistic-plausibility-in-glaucoma Test your visual field online: https://visualfieldtest.com Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support Excerpt: Aspartame, Sucralose, Saccharin, and Stevia: Comparative Mechanistic Plausibility in Glaucoma Introduction People with glaucoma often ask whether diet drinks, artificial sweeteners, or stevia could damage the optic nerve. The question is biologically reasonable because glaucoma is not only an eye-pressure disorder. Retinal ganglion cell injury can also involve vascular dysregulation, impaired endothelial function, oxidative stress, mitochondrial dysfunction, blood-retinal barrier changes, and chronic neuroinflammation. () However, a biologically plausible pathway is not the same as a demonstrated clinical risk. At present, there is no established human evidence that ordinary consumption of aspartame, sucralose, saccharin, or purified steviol glycosides causes glaucoma or accelerates glaucomatous progression. The available evidence is mainly regulatory toxicology, absorption studies, metabolic research, cell experiments, animal studies, and research on cardiovascular or inflammatory outcomes rather than glaucoma itself. Existing glaucoma nutrition reviews do not identify these sweeteners as proven glaucoma risk factors. () The most defensible conclusion is therefore: > For typical intake within established safety limits, all four sweeteners are more likely to be neutral with respect to glaucoma than directly harmful or beneficial. The main potential benefit is indirect: replacing sugar-sweetened foods or beverages may reduce glucose-related vascular stress. The main uncertainty concerns high, chronic intake and individual metabolic or microbiome responses—not a proven direct toxic effect on the optic nerve. How glaucoma physiology relates to sweeteners Glaucoma involves progressive loss of retinal ganglion cells and their optic nerve axons. Elevated intraocular pressure is the most important modifiable risk factor, but some patients continue to lose retinal tissue even when pressure is adequately controlled. This has led to increased interest in blood flow, endothelial function, mitochondrial injury, and immune signaling. () Endothelial function and ocular blood flow The vascular endothelium regulates vessel tone, blood flow, permeability, inflammation, and nitric oxide signaling. Studies of primary open-angle glaucoma have reported systemic vascular abnormalities, including impaired peripheral endothelial function and possible involvement of nitric oxide-related pathways. These observations are particularly relevant to normal-tension glaucoma and other forms in which optic nerve injury occurs at relatively modest eye pressures. () Still, brachial artery flow-mediated dilation is not the same as blood flow at the optic nerve head. A change in systemic vascular function does not automatically cause a change in ocular perfusion, and a laboratory effect on endothelial cells does not establish glaucoma risk. Neuroinflammation and the retinal immune environment The retina contains resident immune cells called microglia, along with astrocytes and Müller cells. Under chronic stress, these cells can release inflammatory mediators such as tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, complement-related proteins, and other signaling molecules. Persistent glial activation may amplify retinal ganglion cell injury. () The blood-retinal barrier normally limits exposure of retinal tissue to circulating substances and inflammatory cells. Barrier disruption can increase vascular leakage and create a more inflammatory environment, but evidence that dietary sweeteners disrupt this barrier in living human eyes is currently lacking. () Basic pharmacology of the four sweeteners For the full table, please open this article on visualfieldtest.com. The United States Food and Drug Administration lists the thresholds above and distinguishes high-purity steviol glycosides from crude stevia leaf products. The World Health Organization Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives uses a lower aspartame threshold of 40 milligrams per kilogram per day, while its table for saccharin, sucralose, and steviol glycosides lists 15, 5, and 4 milligrams per kilogram per day, respectively. () Aspartame Absorption and metabolism Aspartame is a small methyl ester made from two amino acids. It is rapidly broken down in the digestive tract into: Phenylalanine Aspartic acid Methanol The Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives concluded that intact aspartame does not enter the systemic circulation in meaningful amounts. Its metabolites are the same or chemically similar to substances obtained from ordinary foods. () This is important for glaucoma risk assessment. A cell experiment in which retinal neurons are exposed directly to aspartame does not reproduce ordinary human exposure if intact aspartame is absent from the blood. The biologically relevant question would be whether phenylalanine, aspartic acid, methanol, or their downstream products reach the retina at harmful concentrations. People with phenylketonuria, a rare inherited disorder of phenylalanine metabolism, should avoid or strictly limit aspartame according to medical guidance. This is a specific metabolic condition, not evidence that ordinary aspartame intake causes glaucoma in the general population. () Endothelial effects Direct human studies linking aspartame with impaired vascular endothelial function are limited. In one laboratory model using glomerular microvascular endothelial cells, aspartame did not reduce cell viability and, at selected concentrations, helped reduce vascular leakage caused by vascular endothelial growth factor. This finding should not be interpreted as an eye benefit: the cells were kidney-derived, the experiment was performed outside the body, and the vascular stimulus was artificial. () The more clinically relevant comparison is with sugar. Sugar-sweetened beverages can cause acute glucose elevations that increase oxidative stress and impair systemic endothelial function. Replacing those beverages with a noncaloric option may therefore reduce vascular stress, even if the sweetener itself has no special protective effect. () Neuroinflammatory and retinal signals Animal studies have reported oxidative stress, inflammatory signaling, and changes in brain tissue after relatively high or prolonged aspartame exposure. Findings have included increased tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, nuclear factor kappa B signaling, inducible nitric oxide synthase, and glial fibrillary acidic protein. These findings demonstrate biological activity in experimental models, but they do not show that ordinary human intake damages retinal ganglion cells. () A recent retinal study is mechanistically interesting because aspartame increased intracellular calcium in isolated rat retinal neurons, and saccharin produced a similar effect. Excessive intracellular calcium can contribute to neuronal injury in several neurodegenerative diseases. However, the experiment used isolated retinal cells exposed directly to sweeteners, not living animals with glaucoma, and direct exposure to intact aspartame does not mirror its normal human pharmacokinetics. () Overall assessment of aspartame Potential harm: Biologically plausible only in a limited, indirect sense. High-dose animal studies and isolated retinal-cell findings justify continued research but do not establish a dietary glaucoma hazard. Potential benefit: Possible when used instead of sugar-sweetened beverages, particularly if it lowers total sugar intake. Most likely interpretation at ordinary intake: Neutral with respect to glaucoma, provided the person does not have phenylketonuria and intake remains within established limits. Sucralose Absorption and metabolism Sucralose is a chlorinated derivative of sucrose. It is approximately 600 times sweeter than sugar, allowing very small quantities to provide sweetness. In a human pharmacokinetic study, approximately 78 percent of a radiolabeled dose was recovered in feces and approximately 14.5 percent in urine. The material in feces was essentially unchanged sucralose. Most urinary material was also sucralose, with only a small fraction represented by more polar, probably conjugated metabolites. () This means that sucralose is not simply “inert,” but it is also not extensively metabolized into large quantities of reactive compounds. Its strongest potential biological pathway may be through intestinal taste receptors, gut microbial interactions, and metabolic signaling, rather than direct delivery to retinal tissue. Endothelial effects The available human vascular evidence does not show a consistent direct endothelial injury signal. An acute study found that sucralose did not alter brachial artery flow-mediated dilation, and another study in older adults found no acute effect of intestinal sucralose administration on blood pressure or superior mesenteric artery blood flow. These studies were small and short-term, but they do not support a strong immediate vascular toxicity signal. () In a laboratory model of glomerular endothelial cells, sucralose reduced vascular leakage caused by vascular endothe Support the show

    Aspartame, Sucralose, Saccharin, and Stevia: Comparative Mechanistic Plausibility in Glaucoma
See All (233)

Ratings & Reviews

About

Discover the latest science on glaucoma, vision, and longevity. Each episode explores evidence-based supplements for eye health, healthy aging, and lifespan extension. Original articles backed by real scientific research. All source links available at visualfieldtest.com, where you can also take a free visual field test online. Subscribe for weekly insights on glaucoma treatment, glaucoma prevention, vision supplements, and longevity research that could protect your sight and extend your healthspan.MEDICAL DISCLAIMER:This podcast is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. The content presented should not replace professional medical consultation.Glaucoma is a serious condition that can lead to permanent vision loss. Never stop or modify prescribed treatments without consulting your ophthalmologist or healthcare provider.The supplements and research discussed are for informational purposes only. Individual results may vary, and supplements are not FDA-approved to treat, cure, or prevent any disease.Always consult a qualified healthcare professional before starting any new supplement regimen, especially if you have existing eye conditions or are taking medications.The visual field test available at visualfieldtest.com is a screening tool only and does not replace comprehensive eye exams by a licensed professional.

Information

You Might Also Like